Tafamidis meglumine


Tafamidis meglumine

Drug updated on 4/18/2024

Dosage FormCapsule (oral; 80 mg)
Drug ClassTransthyretin stabilizers
Ongoing and
Completed Studies


  • Indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Tafamidis meglumine (Vyndaqel) is indicated for the treatment of cardiomyopathy in adults with wild type or hereditary transthyretin-mediated amyloidosis, reducing cardiovascular mortality and hospitalization.
  • Eight studies have been reviewed to gather information about this drug's efficacy and safety profile.
  • The studies consistently reported tafamidis as efficacious and safe for patients with transthyretin amyloid cardiomyopathy, significantly reducing cardiovascular mortality and all-cause death. However, there was no direct comparison made between tafamidis' effectiveness or safety compared to other drugs within its therapeutic class.
  • Subgroup analysis revealed that the efficacy of tafamidis does not differ significantly between patients with wild-type or hereditary ATTR. However, it was noted that genotypic variability among hereditary ATTR might influence treatment outcomes.
  • Despite positive reports on its impact on mortality rates and hospitalizations due to cardiovascular issues, more randomized controlled trials are needed to validate certain clinical parameters associated with tafamidis use.
  • While indirect comparisons suggest a differentiated landscape of ATTR treatments where Vyndaqel plays a crucial role in managing cardiomyopathy aspects; additional research is required for direct comparisons against other therapies like patisiran and inotersen which focus primarily on peripheral neuropathy aspects of ATTR.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyndaqel (tafamidis meglumine) Prescribing Information.2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines